Top

Journal of Cardiovascular Translational Research

Published in:

01-04-2010

Gender Dimorphisms in Progenitor and Stem Cell Function in Cardiovascular Disease

Authors: Jeremy L. Herrmann, Aaron M. Abarbanell, Brent R. Weil, Mariuxi C. Manukyan, Jeffrey A. Poynter, Yue Wang, Arthur C. Coffey, Daniel R. Meldrum

Published in: Journal of Cardiovascular Translational Research | Issue 2/2010

Abstract

Differences in cardiovascular disease outcomes between men and women have long been recognized and attributed, in part, to gender and sex steroids. Gender dimorphisms also exist with respect to the roles of progenitor and stem cells in post-ischemic myocardial and endothelial repair and regeneration. Understanding how these cells are influenced by donor gender and the recipient hormonal milieu may enable researchers to further account for the gender-related disparities in clinical outcomes as well as utilize the beneficial effects of these hormones to optimize transplanted cell function and survival. This review discusses (1) the cardiovascular effects of sex steroids (specifically estradiol and testosterone); (2) the therapeutic potentials of endothelial progenitor cells, mesenchymal stem cells, and embryonic stem cells; and (3) the direct effect of sex steroids on these cell types.

Kher, A., Meldrum, K. K., Wang, M., Tsai, B. M., Pitcher, J. M., & Meldrum, D. R. (2005). Cellular and molecular mechanisms of sex differences in renal ischemia–reperfusion injury. Cardiovascular Research, 67, 594–603.PubMedCrossRef

Choudhry, M. A., Schwacha, M. G., Hubbard, W. J., Kerby, J. D., Rue, L. W., Bland, K. I., et al. (2005). Gender differences in acute response to trauma–hemorrhage. Shock, 24(Suppl 1), 101–106.PubMedCrossRef

Choudhry, M. A., Bland, K. I., & Chaudry, I. H. (2006). Gender and susceptibility to sepsis following trauma. Endocr Metab Immune Disord Drug Targets, 6, 127–135.PubMed

Stampfer, M. J., Colditz, G. A., Willett, W. C., Manson, J. E., Rosner, B., Speizer, F. E., et al. (1991). Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses’ health study. New England Journal of Medicine, 325, 756–762.PubMed

Kher, A., Wang, M., Tsai, B. M., Pitcher, J. M., Greenbaum, E. S., Nagy, R. D., et al. (2005). Sex differences in the myocardial inflammatory response to acute injury. Shock, 23, 1–10.PubMedCrossRef

Grady, D., Rubin, S. M., Petitti, D. B., Fox, C. S., Black, D., Ettinger, B., et al. (1992). Hormone therapy to prevent disease and prolong life in postmenopausal women. Annals of Internal Medicine, 117, 1016–1037.PubMed

Urbich, C. & Dimmeler, S. (2004). Endothelial progenitor cells: Characterization and role in vascular biology. Circulation Research, 95, 343–353.PubMedCrossRef

Crisostomo, P. R., Wang, M., Markel, T. A., Lahm, T., Abarbanell, A. M., Herrmann, J. L., et al. (2007). Stem cell mechanisms and paracrine effects: Potential in cardiac surgery. Shock, 28, 375–383.PubMedCrossRef

Crisostomo, P. R., Abarbanell, A. M., Wang, M., Lahm, T., Wang, Y., & Meldrum, D. R. (2008). Embryonic stem cells attenuate myocardial dysfunction and inflammation after surgical global ischemia via paracrine actions. American Journal of Physiology. Heart and Circulatory Physiology, 295, H1726–H1735.PubMedCrossRef

10.

Farhat, M. Y., Lavigne, M. C., & Ramwell, P. W. (1996). The vascular protective effects of estrogen. FASEB Journal, 10, 615–624.PubMed

11.

Mosselman, S., Polman, J., & Dijkema, R. (1996). ER beta: Identification and characterization of a novel human estrogen receptor. FEBS Letters, 392, 49–53.PubMedCrossRef

12.

Villablanca, A. C., Tenwolde, A., Lee, M., Huck, M., Mumenthaler, S., & Rutledge, J. C. (2009). 17beta-estradiol prevents early-stage atherosclerosis in estrogen receptor-alpha deficient female mice. J Cardiovasc Transl Res, 2, 289–299.PubMedCrossRef

13.

Nilsson, S., Makela, S., Treuter, E., Tujague, M., Thomsen, J., Andersson, G., et al. (2001). Mechanisms of estrogen action. Physiological Reviews, 81, 1535–1565.PubMed

14.

Liu, H., Liu, K., & Bodenner, D. L. (2005). Estrogen receptor inhibits interleukin-6 gene expression by disruption of nuclear factor kappaB transactivation. Cytokine, 31, 251–257.PubMedCrossRef

15.

Hamada, H., Kim, M. K., Iwakura, A., Ii, M., Thorne, T., Qin, G., et al. (2006). Estrogen receptors alpha and beta mediate contribution of bone marrow-derived endothelial progenitor cells to functional recovery after myocardial infarction. Circulation, 114, 2261–2270.PubMedCrossRef

16.

Shao, R., Egecioglu, E., Weijdegard, B., Kopchick, J. J., Fernandez-Rodriguez, J., Andersson, N., et al. (2007). Dynamic regulation of estrogen receptor-alpha isoform expression in the mouse fallopian tube: Mechanistic insight into estrogen-dependent production and secretion of insulin-like growth factors. Am J Physiol Endocrinol Metab, 293, E1430–E1442.PubMedCrossRef

17.

Matthews, J., Almlof, T., Kietz, S., Leers, J., & Gustafsson, J. A. (2005). Estrogen receptor-alpha regulates SOCS-3 expression in human breast cancer cells. Biochemical and Biophysical Research Communications, 335, 168–174.PubMedCrossRef

18.

Roggia, C., Gao, Y., Cenci, S., Weitzmann, M. N., Toraldo, G., Isaia, G., et al. (2001). Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo. Proceedings of the National Academy of Sciences of the United States of America, 98, 13960–13965.PubMedCrossRef

19.

Leung, S. W., Teoh, H., Keung, W., & Man, R. Y. (2007). Non-genomic vascular actions of female sex hormones: Physiological implications and signalling pathways. Clinical and Experimental Pharmacology and Physiology, 34, 822–826.PubMedCrossRef

20.

Kim, K. H., Moriarty, K., & Bender, J. R. (2008). Vascular cell signaling by membrane estrogen receptors. Steroids, 73, 864–869.PubMedCrossRef

21.

Krasinski, K., Spyridopoulos, I., Asahara, T., van der Zee, R., Isner, J. M., & Losordo, D. W. (1997). Estradiol accelerates functional endothelial recovery after arterial injury. Circulation, 95, 1768–1772.PubMed

22.

Brouchet, L., Krust, A., Dupont, S., Chambon, P., Bayard, F., & Arnal, J. F. (2001). Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor-alpha but not estrogen receptor-beta. Circulation, 103, 423–428.PubMed

23.

Toutain, C. E., Filipe, C., Billon, A., Fontaine, C., Brouchet, L., Guery, J. C., et al. (2009). Estrogen receptor alpha expression in both endothelium and hematopoietic cells is required for the accelerative effect of estradiol on reendothelialization. Arteriosclerosis, Thrombosis and Vascular Biology, 29, 1543–1550.CrossRef

24.

Makela, S., Savolainen, H., Aavik, E., Myllarniemi, M., Strauss, L., Taskinen, E., et al. (1999). Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors alpha and beta. Proceedings of the National Academy of Sciences of the United States of America, 96, 7077–7082.PubMedCrossRef

25.

Wang, M., Wang, Y., Weil, B., Abarbanell, A., Herrmann, J., Tan, J., et al. (2009). Estrogen receptor beta mediates increased activation of PI3K/Akt signaling and improved myocardial function in female hearts following acute ischemia. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 296, R972–R978.PubMed

26.

Iafrati, M. D., Karas, R. H., Aronovitz, M., Kim, S., Sullivan, T. R., Jr., Lubahn, D. B., et al. (1997). Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nature Medicine, 3, 545–548.PubMedCrossRef

27.

Karas, R. H., Hodgin, J. B., Kwoun, M., Krege, J. H., Aronovitz, M., Mackey, W., et al. (1999). Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proceedings of the National Academy of Sciences of the United States of America, 96, 15133–15136.PubMedCrossRef

28.

Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., et al. (1998). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA, 280, 605–613.PubMedCrossRef

29.

Grady, D., Herrington, D., Bittner, V., Blumenthal, R., Davidson, M., Hlatky, M., et al. (2002). Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA, 288, 49–57.PubMedCrossRef

30.

Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women’s Health Initiative randomized controlled trial. JAMA, 288, 321–333.PubMedCrossRef

31.

Anderson, G. L., Limacher, M., Assaf, A. R., Bassford, T., Beresford, S. A., Black, H., et al. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women’s Health Initiative randomized controlled trial. JAMA, 291, 1701–1712.PubMedCrossRef

32.

Wang, M., Wang, Y., Abarbanell, A., Tan, J., Weil, B., Herrmann, J., et al. (2009). Both endogenous and exogenous testosterone decrease myocardial STAT3 activation and SOCS3 expression after acute ischemia and reperfusion. Surgery, 146, 138–144.PubMedCrossRef

33.

Alexandersen, P., Haarbo, J., Byrjalsen, I., Lawaetz, H., & Christiansen, C. (1999). Natural androgens inhibit male atherosclerosis: A study in castrated, cholesterol-fed rabbits. Circulation Research, 84, 813–819.PubMed

34.

Dockery, F., Bulpitt, C. J., Donaldson, M., Fernandez, S., & Rajkumar, C. (2003). The relationship between androgens and arterial stiffness in older men. Journal of the American Geriatrics Society, 51, 1627–1632.PubMedCrossRef

35.

Hougaku, H., Fleg, J. L., Najjar, S. S., Lakatta, E. G., Harman, S. M., Blackman, M. R., et al. (2006). Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements. Am J Physiol Endocrinol Metab, 290, E234–E242.PubMedCrossRef

36.

Kang, S. M., Jang, Y., Kim, J. Y., Chung, N., Cho, S. Y., Chae, J. S., et al. (2002). Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. American Journal of Cardiology, 89, 862–864.PubMedCrossRef

37.

Rosano, G. M., Leonardo, F., Pagnotta, P., Pelliccia, F., Panina, G., Cerquetani, E., et al. (1999). Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation, 99, 1666–1670.PubMed

38.

Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., et al. (1997). Isolation of putative progenitor endothelial cells for angiogenesis. Science, 275, 964–967.PubMedCrossRef

39.

Kocher, A. A., Schuster, M. D., Szabolcs, M. J., Takuma, S., Burkhoff, D., Wang, J., et al. (2001). Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nature Medicine, 7, 430–436.PubMedCrossRef

40.

Takahashi, T., Kalka, C., Masuda, H., Chen, D., Silver, M., Kearney, M., et al. (1999). Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nature Medicine, 5, 434–438.PubMedCrossRef

41.

Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., et al. (2004). Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nature Medicine, 10, 858–864.PubMedCrossRef

42.

Elmadbouh, I., Haider, H., Jiang, S., Idris, N. M., Lu, G., & Ashraf, M. (2007). Ex vivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium. Journal of Molecular and Cellular Cardiology, 42, 792–803.PubMedCrossRef

43.

Li, B., Sharpe, E. E., Maupin, A. B., Teleron, A. A., Pyle, A. L., Carmeliet, P., et al. (2006). VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB Journal, 20, 1495–1497.PubMedCrossRef

44.

Aicher, A., Heeschen, C., Mildner-Rihm, C., Urbich, C., Ihling, C., Technau-Ihling, K., et al. (2003). Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nature Medicine, 9, 1370–1376.PubMedCrossRef

45.

Shintani, S., Murohara, T., Ikeda, H., Ueno, T., Honma, T., Katoh, A., et al. (2001). Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation, 103, 2776–2779.PubMedCrossRef

46.

Gill, M., Dias, S., Hattori, K., Rivera, M. L., Hicklin, D., Witte, L., et al. (2001). Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circulation Research, 88, 167–174.PubMed

47.

Asahara, T., Takahashi, T., Masuda, H., Kalka, C., Chen, D., Iwaguro, H., et al. (1999). VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO Journal, 18, 3964–3972.PubMedCrossRef

48.

Kalka, C., Masuda, H., Takahashi, T., Kalka-Moll, W. M., Silver, M., Kearney, M., et al. (2000). Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proceedings of the National Academy of Sciences of the United States of America, 97, 3422–3427.PubMedCrossRef

49.

Kawamoto, A., Gwon, H. C., Iwaguro, H., Yamaguchi, J. I., Uchida, S., Masuda, H., et al. (2001). Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation, 103, 634–637.PubMed

50.

Jujo, K., Ii, M., & Losordo, D. W. (2008). Endothelial progenitor cells in neovascularization of infarcted myocardium. Journal of Molecular and Cellular Cardiology, 45, 530–544.PubMedCrossRef

51.

Kang, H. J., Kim, H. S., Zhang, S. Y., Park, K. W., Cho, H. J., Koo, B. K., et al. (2004). Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: The MAGIC cell randomised clinical trial. Lancet, 363, 751–756.PubMedCrossRef

52.

Hill, J. M., Zalos, G., Halcox, J. P., Schenke, W. H., Waclawiw, M. A., Quyyumi, A. A., et al. (2003). Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. New England Journal of Medicine, 348, 593–600.PubMedCrossRef

53.

Werner, N., Kosiol, S., Schiegl, T., Ahlers, P., Walenta, K., Link, A., et al. (2005). Circulating endothelial progenitor cells and cardiovascular outcomes. New England Journal of Medicine, 353, 999–1007.PubMedCrossRef

54.

Scheubel, R. J., Zorn, H., Silber, R. E., Kuss, O., Morawietz, H., Holtz, J., et al. (2003). Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting. Journal of the American College of Cardiology, 42, 2073–2080.PubMedCrossRef

55.

Tepper, O. M., Galiano, R. D., Capla, J. M., Kalka, C., Gagne, P. J., Jacobowitz, G. R., et al. (2002). Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation, 106, 2781–2786.PubMedCrossRef

56.

Loomans, C. J., de Koning, E. J., Staal, F. J., Rookmaaker, M. B., Verseyden, C., de Boer, H. C., et al. (2004). Endothelial progenitor cell dysfunction: A novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes, 53, 195–199.PubMedCrossRef

57.

Simper, D., Wang, S., Deb, A., Holmes, D., McGregor, C., Frantz, R., et al. (2003). Endothelial progenitor cells are decreased in blood of cardiac allograft patients with vasculopathy and endothelial cells of noncardiac origin are enriched in transplant atherosclerosis. Circulation, 108, 143–149.PubMedCrossRef

58.

George, J., Goldstein, E., Abashidze, S., Deutsch, V., Shmilovich, H., Finkelstein, A., et al. (2004). Circulating endothelial progenitor cells in patients with unstable angina: Association with systemic inflammation. European Heart Journal, 25, 1003–1008.PubMedCrossRef

59.

Choi, J. H., Kim, K. L., Huh, W., Kim, B., Byun, J., Suh, W., et al. (2004). Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 1246–1252.PubMedCrossRef

60.

Imanishi, T., Moriwaki, C., Hano, T., & Nishio, I. (2005). Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension. Journal of Hypertension, 23, 1831–1837.PubMedCrossRef

61.

Ghani, U., Shuaib, A., Salam, A., Nasir, A., Shuaib, U., Jeerakathil, T., et al. (2005). Endothelial progenitor cells during cerebrovascular disease. Stroke, 36, 151–153.PubMedCrossRef

62.

Iwakura, A., Luedemann, C., Shastry, S., Hanley, A., Kearney, M., Aikawa, R., et al. (2003). Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation, 108, 3115–3121.PubMedCrossRef

63.

Strehlow, K., Werner, N., Berweiler, J., Link, A., Dirnagl, U., Priller, J., et al. (2003). Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation, 107, 3059–3065.PubMedCrossRef

64.

Zhao, X., Huang, L., Yin, Y., Fang, Y., Zhao, J., & Chen, J. (2008). Estrogen induces endothelial progenitor cells proliferation and migration by estrogen receptors and PI3K-dependent pathways. Microvascular Research, 75, 45–52.PubMedCrossRef

65.

Iwakura, A., Shastry, S., Luedemann, C., Hamada, H., Kawamoto, A., Kishore, R., et al. (2006). Estradiol enhances recovery after myocardial infarction by augmenting incorporation of bone marrow-derived endothelial progenitor cells into sites of ischemia-induced neovascularization via endothelial nitric oxide synthase-mediated activation of matrix metalloproteinase-9. Circulation, 113, 1605–1614.PubMedCrossRef

66.

Fontaine, V., Filipe, C., Werner, N., Gourdy, P., Billon, A., Garmy-Susini, B., et al. (2006). Essential role of bone marrow fibroblast growth factor-2 in the effect of estradiol on reendothelialization and endothelial progenitor cell mobilization. American Journal of Pathology, 169, 1855–1862.PubMedCrossRef

67.

Rousseau, A., Ayoubi, F., Deveaux, C., Charbit, B., Delmau, C., Christin-Maitre, S., et al. (2009). Impact of age and gender interaction on circulating endothelial progenitor cells in healthy subjects. Fertility and Sterility (in press).

68.

Lemieux, C., Cloutier, I., & Tanguay, J. F. (2009). Menstrual cycle influences endothelial progenitor cell regulation: A link to gender differences in vascular protection? International Journal of Cardiology, 136, 200–210.PubMedCrossRef

69.

Fadini, G. P., de Kreutzenberg, S., Albiero, M., Coracina, A., Pagnin, E., Baesso, I., et al. (2008). Gender differences in endothelial progenitor cells and cardiovascular risk profile: The role of female estrogens. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 997–1004.PubMedCrossRef

70.

Hoetzer, G. L., MacEneaney, O. J., Irmiger, H. M., Keith, R., Van Guilder, G. P., Stauffer, B. L., et al. (2007). Gender differences in circulating endothelial progenitor cell colony-forming capacity and migratory activity in middle-aged adults. American Journal of Cardiology, 99, 46–48.PubMedCrossRef

71.

Foresta, C., Caretta, N., Lana, A., De Toni, L., Biagioli, A., Ferlin, A., et al. (2006). Reduced number of circulating endothelial progenitor cells in hypogonadal men. Journal of Clinical Endocrinology and Metabolism, 91, 4599–4602.PubMedCrossRef

72.

Foresta, C., Zuccarello, D., De Toni, L., Garolla, A., Caretta, N., & Ferlin, A. (2008). Androgens stimulate endothelial progenitor cells through an androgen receptor-mediated pathway. Clinical Endocrinology (Oxford), 68, 284–289.

73.

Fadini, G. P., Albiero, M., Cignarella, A., Bolego, C., Pinna, C., Boscaro, E., et al. (2009). Effects of androgens on endothelial progenitor cells in vitro and in vivo. Clinical Science (London), 117, 355–364.CrossRef

74.

Kim, S. W., Hwang, J. H., Cheon, J. M., Park, N. S., Park, S. E., Park, S. J., et al. (2005). Direct and indirect effects of androgens on survival of hematopoietic progenitor cells in vitro. Journal of Korean Medical Science, 20, 409–416.PubMedCrossRef

75.

Garolla, A., D’Inca, R., Checchin, D., Biagioli, A., De Toni, L., Nicoletti, V., et al. (2009). Reduced endothelial progenitor cell number and function in inflammatory bowel disease: A possible link to the pathogenesis. American Journal of Gastroenterology, 104, 2500–2507.PubMedCrossRef

76.

Conget, P. A., & Minguell, J. J. (1999). Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. Journal of Cellular Physiology, 181, 67–73.PubMedCrossRef

77.

Toma, C., Pittenger, M. F., Cahill, K. S., Byrne, B. J., & Kessler, P. D. (2002). Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation, 105, 93–98.PubMedCrossRef

78.

Crisostomo, P. R., Markel, T. A., Wang, Y., & Meldrum, D. R. (2008). Surgically relevant aspects of stem cell paracrine effects. Surgery, 143, 577–581.PubMedCrossRef

79.

Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., et al. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99, 3838–3843.PubMedCrossRef

80.

Abdel-Latif, A., Bolli, R., Tleyjeh, I. M., Montori, V. M., Perin, E. C., Hornung, C. A., et al. (2007). Adult bone marrow-derived cells for cardiac repair: A systematic review and meta-analysis. Archives of Internal Medicine, 167, 989–997.PubMedCrossRef

81.

Lipinski, M. J., Biondi-Zoccai, G. G., Abbate, A., Khianey, R., Sheiban, I., Bartunek, J., et al. (2007). Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: A collaborative systematic review and meta-analysis of controlled clinical trials. Journal of the American College of Cardiology, 50, 1761–1767.PubMedCrossRef

82.

Crisostomo, P. R., Wang, M., Herring, C. M., Morrell, E. D., Seshadri, P., Meldrum, K. K., et al. (2006). Sex dimorphisms in activated mesenchymal stem cell function. Shock, 26, 571–574.PubMedCrossRef

83.

Hiasa, K., Egashira, K., Kitamoto, S., Ishibashi, M., Inoue, S., Ni, W., et al. (2004). Bone marrow mononuclear cell therapy limits myocardial infarct size through vascular endothelial growth factor. Basic Research in Cardiology, 99, 165–172.PubMedCrossRef

84.

Meldrum, D. R. (1998). Tumor necrosis factor in the heart. American Journal of Physiology, 274, R577–R595.PubMed

85.

Crisostomo, P. R., Markel, T. A., Wang, M., Lahm, T., Lillemoe, K. D., & Meldrum, D. R. (2007). In the adult mesenchymal stem cell population, source gender is a biologically relevant aspect of protective power. Surgery, 142, 215–221.PubMedCrossRef

86.

Erwin, G. S., Crisostomo, P. R., Wang, Y., Wang, M., Markel, T. A., Guzman, M., et al. (2009). Estradiol-treated mesenchymal stem cells improve myocardial recovery after ischemia. Journal of Surgical Research, 152, 319–324.PubMedCrossRef

87.

Wang, M., Tan, J., Coffey, A., Fehrenbacher, J., Weil, B. R., & Meldrum, D. R. (2009). Signal transducer and activator of transcription 3-stimulated hypoxia inducible factor-1alpha mediates estrogen receptor-alpha-induced mesenchymal stem cell vascular endothelial growth factor production. Journal of Thoracic and Cardiovascular Surgery, 138, 163–171, 171 e161.PubMedCrossRef

88.

Forsythe, J. A., Jiang, B. H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., et al. (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Molecular and Cellular Biology, 16, 4604–4613.PubMed

89.

Wang, M., Zhang, W., Crisostomo, P., Markel, T., Meldrum, K. K., Fu, X. Y., et al. (2007). STAT3 mediates bone marrow mesenchymal stem cell VEGF production. Journal of Molecular and Cellular Cardiology, 42, 1009–1015.PubMedCrossRef

90.

Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., et al. (2002). Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene, 21, 2000–2008.PubMedCrossRef

91.

Platt, D. H., Bartoli, M., El-Remessy, A. B., Al-Shabrawey, M., Lemtalsi, T., Fulton, D., et al. (2005). Peroxynitrite increases VEGF expression in vascular endothelial cells via STAT3. Free Radical Biology and Medicine, 39, 1353–1361.PubMedCrossRef

92.

Xu, Q., Briggs, J., Park, S., Niu, G., Kortylewski, M., Zhang, S., et al. (2005). Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene, 24, 5552–5560.PubMedCrossRef

93.

Gao, H., Bryzgalova, G., Hedman, E., Khan, A., Efendic, S., Gustafsson, J. A., et al. (2006). Long-term administration of estradiol decreases expression of hepatic lipogenic genes and improves insulin sensitivity in ob/ob mice: A possible mechanism is through direct regulation of signal transducer and activator of transcription 3. Molecular Endocrinology, 20, 1287–1299.PubMedCrossRef

94.

Yun, S. P., Lee, M. Y., Ryu, J. M., Song, C. H., & Han, H. J. (2009). Role of HIF-1alpha and VEGF in human mesenchymal stem cell proliferation by 17beta-estradiol: Involvement of PKC, PI3K/Akt, and MAPKs. American Journal of Physiology. Cell Physiology, 296, C317–C326.PubMedCrossRef

95.

Zhou, S., Turgeman, G., Harris, S. E., Leitman, D. C., Komm, B. S., Bodine, P. V., et al. (2003). Estrogens activate bone morphogenetic protein-2 gene transcription in mouse mesenchymal stem cells. Molecular Endocrinology, 17, 56–66.PubMedCrossRef

96.

Wang, M., Tsai, B. M., Crisostomo, P. R., & Meldrum, D. R. (2006). Tumor necrosis factor receptor 1 signaling resistance in the female myocardium during ischemia. Circulation, 114, I282–I289.PubMedCrossRef

97.

Crisostomo, P. R., Wang, M., Herring, C. M., Markel, T. A., Meldrum, K. K., Lillemoe, K. D., et al. (2007). Gender differences in injury induced mesenchymal stem cell apoptosis and VEGF, TNF, IL-6 expression: Role of the 55 kDa TNF receptor (TNFR1). Journal of Molecular and Cellular Cardiology, 42, 142–149.PubMedCrossRef

98.

Markel, T. A., Crisostomo, P. R., Wang, M., Wang, Y., Lahm, T., Novotny, N. M., et al. (2008). TNFR1 signaling resistance associated with female stem cell cytokine production is independent of TNFR2-mediated pathways. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 295, R1124–R1130.PubMed

99.

DiSilvio, L., Jameson, J., Gamie, Z., Giannoudis, P. V., & Tsiridis, E. (2006). In vitro evaluation of the direct effect of estradiol on human osteoblasts (HOB) and human mesenchymal stem cells (h-MSCs). Injury, 37(Suppl 3), S33–S42.PubMedCrossRef

100.

Hong, L., Colpan, A., & Peptan, I. A. (2006). Modulations of 17-beta estradiol on osteogenic and adipogenic differentiations of human mesenchymal stem cells. Tissue Engineering, 12, 2747–2753.PubMedCrossRef

101.

Zhou, S., Zilberman, Y., Wassermann, K., Bain, S. D., Sadovsky, Y., & Gazit, D. (2001). Estrogen modulates estrogen receptor alpha and beta expression, osteogenic activity, and apoptosis in mesenchymal stem cells (MSCs) of osteoporotic mice. Journal of Cellular Biochemistry. Supplement, Suppl 36, 144–155.PubMedCrossRef

102.

Cha, Y., Kwon, S. J., Seol, W., & Park, K. S. (2008). Estrogen receptor-alpha mediates the effects of estradiol on telomerase activity in human mesenchymal stem cells. Molecules and Cells, 26, 454–458.PubMed

103.

Ray, R., Herring, C. M., Markel, T. A., Crisostomo, P. R., Wang, M., Weil, B., et al. (2008). Deleterious effects of endogenous and exogenous testosterone on mesenchymal stem cell VEGF production. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 294, R1498–R1503.PubMed

104.

Min, J. Y., Yang, Y., Sullivan, M. F., Ke, Q., Converso, K. L., Chen, Y., et al. (2003). Long-term improvement of cardiac function in rats after infarction by transplantation of embryonic stem cells. Journal of Thoracic and Cardiovascular Surgery, 125, 361–369.PubMedCrossRef

105.

Leor, J., Gerecht, S., Cohen, S., Miller, L., Holbova, R., Ziskind, A., et al. (2007). Human embryonic stem cell transplantation to repair the infarcted myocardium. Heart, 93, 1278–1284.PubMedCrossRef

106.

Nussbaum, J., Minami, E., Laflamme, M. A., Virag, J. A., Ware, C. B., Masino, A., et al. (2007). Transplantation of undifferentiated murine embryonic stem cells in the heart: Teratoma formation and immune response. FASEB Journal, 21, 1345–1357.PubMedCrossRef

107.

Behfar, A., Zingman, L. V., Hodgson, D. M., Rauzier, J. M., Kane, G. C., Terzic, A., et al. (2002). Stem cell differentiation requires a paracrine pathway in the heart. FASEB Journal, 16, 1558–1566.PubMedCrossRef

108.

Behfar, A., Perez-Terzic, C., Faustino, R. S., Arrell, D. K., Hodgson, D. M., Yamada, S., et al. (2007). Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. Journal of Experimental Medicine, 204, 405–420.PubMedCrossRef

109.

Laflamme, M. A., Chen, K. Y., Naumova, A. V., Muskheli, V., Fugate, J. A., Dupras, S. K., et al. (2007). Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nature Biotechnology, 25, 1015–1024.PubMedCrossRef

110.

Caspi, O., Huber, I., Kehat, I., Habib, M., Arbel, G., Gepstein, A., et al. (2007). Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts. Journal of the American College of Cardiology, 50, 1884–1893.PubMedCrossRef

111.

Nelson, T. J., Martinez-Fernandez, A., Yamada, S., Perez-Terzic, C., Ikeda, Y., & Terzic, A. (2009). Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation, 120, 408–416.PubMedCrossRef

112.

Hong, S. H., Nah, H. Y., Lee, Y. J., Lee, J. W., Park, J. H., Kim, S. J., et al. (2004). Expression of estrogen receptor-alpha and -beta, glucocorticoid receptor, and progesterone receptor genes in human embryonic stem cells and embryoid bodies. Molecules and Cells, 18, 320–325.PubMed

113.

Han, H. J., Heo, J. S., & Lee, Y. J. (2006). Estradiol-17beta stimulates proliferation of mouse embryonic stem cells: Involvement of MAPKs and CDKs as well as protooncogenes. American Journal of Physiology. Cell Physiology, 290, C1067–C1075.PubMedCrossRef

114.

Chang, C. Y., Hsuuw, Y. D., Huang, F. J., Shyr, C. R., Chang, S. Y., Huang, C. K., et al. (2006). Androgenic and antiandrogenic effects and expression of androgen receptor in mouse embryonic stem cells. Fertility and Sterility, 85(Suppl 1), 1195–1203.PubMedCrossRef

115.

Goldman-Johnson, D. R., de Kretser, D. M., & Morrison, J. R. (2008). Evidence that androgens regulate early developmental events, prior to sexual differentiation. Endocrinology, 149, 5–14.PubMedCrossRef

116.

Arrell, D. K., Niederlander, N. J., Faustino, R. S., Behfar, A., & Terzic, A. (2008). Cardioinductive network guiding stem cell differentiation revealed by proteomic cartography of tumor necrosis factor alpha-primed endodermal secretome. Stem Cells, 26, 387–400.PubMedCrossRef

117.

Nelson, T. J., Faustino, R. S., Chiriac, A., Crespo-Diaz, R., Behfar, A., & Terzic, A. (2008). CXCR4+/FLK-1+ biomarkers select a cardiopoietic lineage from embryonic stem cells. Stem Cells, 26, 1464–1473.PubMedCrossRef

118.

Keaney, J. F., Jr., Shwaery, G. T., Xu, A., Nicolosi, R. J., Loscalzo, J., Foxall, T. L., et al. (1994). 17beta-estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine. Circulation, 89, 2251–2259.PubMed

119.

Moskowitz, M. S., Moskowitz, A. A., Bradford, W. L., Jr., & Wissler, R. W. (1956). Changes in serum lipids and coronary arteries of the rat in response to estrogens. AMA Archives of Pathology, 61, 245–263.

120.

Adams, M. R., Kaplan, J. R., Manuck, S. B., Koritnik, D. R., Parks, J. S., Wolfe, M. S., et al. (1990). Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: Lack of an effect of added progesterone. Arteriosclerosis, 10, 1051–1057.PubMed

121.

Palmer, R. M., Ferrige, A. G., & Moncada, S. (1987). Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature, 327, 524–526.PubMedCrossRef

122.

Bath, P. M., Hassall, D. G., Gladwin, A. M., Palmer, R. M., & Martin, J. F. (1991). Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arteriosclerosis and Thrombosis, 11, 254–260.PubMed

123.

Radomski, M. W., Palmer, R. M., & Moncada, S. (1987). Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet, 2, 1057–1058.PubMedCrossRef

124.

Lahm, T., Patel, K. M., Crisostomo, P. R., Markel, T. A., Wang, M., Herring, C., et al. (2007). Endogenous estrogen attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction: The effects of sex and menstrual cycle. Am J Physiol Endocrinol Metab, 293, E865–E871.PubMedCrossRef

Title: Gender Dimorphisms in Progenitor and Stem Cell Function in Cardiovascular Disease
Authors: Jeremy L. Herrmann
Aaron M. Abarbanell
Brent R. Weil
Mariuxi C. Manukyan
Jeffrey A. Poynter
Yue Wang
Arthur C. Coffey
Daniel R. Meldrum
Publication date: 01-04-2010
Publisher: Springer US
Published in: Journal of Cardiovascular Translational Research / Issue 2/2010
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-009-9149-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Gender Dimorphisms in Progenitor and Stem Cell Function in Cardiovascular Disease

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Hypoxia-Inducible Factor 1-Alpha Release After Intracoronary Versus Intramyocardial Stem Cell Therapy in Myocardial Infarction

Preconditioning and Stem Cell Survival

COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133+ Bone Marrow Stem Cells to Placebo in Patients After Acute Myocardial Infarction and Left Ventricular Dysfunction: Study Rationale and Design

Stem Cell Biobanks

Dynamics of Progenitor Cells and Ventricular Assist Device Intervention

Efficiency of Intramyocardial Injections of Autologous Bone Marrow Mononuclear Cells in Patients with Ischemic Heart Failure: A Randomized Study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page